

TABLE OF CONTENTS

EXECUTIVE SUMMARY.....	5	5. VALUATION OF COMPANIES OF THE INDUSTRY...	102
INTRODUCTION.....	8	5.1 Valuation methodology.....	103
1. GENERAL INFORMATION.....	9	5.2 Valuation of companies of the industry (2019-2023).....	104
1.1 Definition and categories of clinical studies.....	10	6. MARKET.....	105
1.2 Industry general facts & figures.....	14	6.1 Domestic clinical studies market (2015–2024)...	106
2. INSTITUTIONAL FRAMEWORK.....	17	6.2 Number of clinical studies.....	107
3. DEMAND.....	26	6.3 Clinical studies structure by phase (2015–2024)	108
3.1 Determinants of demand.....	27	6.4 Distribution of clinical studies by health condition category (2015–2024).....	109
3.2 Analysis of selected determinants of demand....	31	6.5 Distribution of clinical studies by health condition subcategory (2015–2024).....	110
4. SUPPLY.....	72	6.6 Clinical studies by age group and gender (2015–2024).....	111
4.1 Turnover growth of major CRO companies of the industry (2019-2023).....	74	6.7 Clinical studies by number of participants (2015–2024).....	112
4.2 Ranking of major CRO companies based on turnover 2023.....	76	6.8 Porter’s five forces.....	113
4.3 Financial analysis of the industry (2019-2023)...	78	7. INTERNATIONAL MARKET.....	119
4.4 Comparison of financial indicators for groups of companies of the industry (2023).....	85	7.1 Number of clinical studies worldwide (2015–2024).....	120
4.5 Assets-Liabilities structure of the consolidated balance sheet	87	7.2 Number of clinical studies worldwide by phase (2015–2024).....	121
4.6 Development of companies’ financial results....	88	7.3 Number of clinical studies by geographic region (2015–2024).....	122
4.7 Comparative assessment of financial indicators for major companies of the industry (2023).....	92		
4.8 Evolution of financial indicators of major companies of the industry (2019-2023).....	97		

TABLE OF CONTENTS

7.4 Distribution of clinical studies by health condition category (2015–2024).....	123
7.5 Number of clinical studies by country (2023).....	124
7.6 Pharmaceutical expenditures for research and development.....	125
7.7 Patent applications in Europe by industry.....	129
8. CONCLUSIONS - PROSPECTS	130
8.1 SWOT Analysis.....	131
8.2 Main findings and prospects.....	132
APPENDIX	
Financial indicators of companies of the industry (2019-2023).....	135
A. Capital structure and financial leverage indicators	136
B. Liquidity indicators.....	148
C. Activity indicators.....	152
D. Performance indicators.....	162
Financial formulas.....	172
SOURCES & BIBLIOGRAPHY	173